Allogeneic ABCB5-positive Stem Cells for Treatment of PAOD

A Randomised, Placebo-controlled, Double-blind, Interventional, Multicenter, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-PAOD for the Treatment of Peripheral Arterial Occlusive Disease (PAOD)

The aim of this clinical trial is to investigate the efficacy (by monitoring the wound size reduction of Peripheral Arterial Occlusive Disease-related clinically relevant ulcers) and safety (by monitoring adverse events) of one dose of allo-APZ2-PAOD administered intramuscularly into an affected lower leg of patients with Peripheral Arterial Occlusive Disease.

Study Overview

• Status: Terminated
• Conditions: Peripheral Arterial Occlusive Disease
• Intervention / Treatment: Drug: Placebo; Biological: allo-APZ2-PAOD

Detailed Description

This is an interventional, randomised, placebo-controlled, double-blind phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-PAOD for the treatment of Peripheral Arterial Occlusive Disease patients with non-healing ulcers. The allogeneic investigational product allo-APZ2-PAOD contains skin-derived ABCB5-positive mesenchymal stem cells isolated from skin tissue of healthy donors and stored in a donor cell bank.

Patients are followed up for efficacy for 12 weeks by clinical visits at the clinical trial sites to monitor wound healing. The wound healing process of all relevant ulcers will be documented by standardized photography and the quality of the wound healing process will be assessed.

Pain will be assessed using a numerical rating scale and quality of life will be investigated with a standardized and validated questionnaire. To assess long-term safety of allo-APZ2-PAOD three follow-up visits at Months 6, 9 and 12 post IMP applications are included. An unblinded external Independent Data Monitoring Committee (IDMC) will continuously monitor safety throughout the study.

• Study Type: Interventional
• Enrollment (Actual): 24
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Austria
  • Graz, Austria, 8036
    • LKH-Univ. Klinikum Graz
  • Linz, Austria, 4021
    • Konventhospital der Barmherzigen Brüder Linz
  • Wien, Austria, 1140
    • Hanusch-Krankenhaus Wien
• Czechia
  • Ústí Nad Labem, Czechia, 401 13
    • Krajska zdravotni a.s. - Masarykova nemocnice v Usti nad Labem, o.z.
• Germany
  • Berlin, Germany, 10787
    • Franziskus-Krankenhaus Berlin
  • Dresden, Germany, 01307
    • Universitätsklinikum "Carl Gustav Carus" der TU Dresden
  • Freital, Germany, 01705
    • Helios Weißeritztal-Kliniken Klinikum Freital
  • Hamburg, Germany, 20246
    • Universitäres Herzzentrum Hamburg GmbH (UHZ)
  • Hamburg, Germany, 21075
    • Asklepios Klinikum Harburg
  • Heidelberg, Germany, 69120
    • Universitätsklinikum Heidelberg
  • Heidelberg, Germany, 69115
    • St. Josefskrankenhaus Heidelberg GmbH
  • Karlsbad, Germany, 76307
    • SRH Klinikum Karlsbad-Langensteinbach GmbH
  • Kiel, Germany, 24105
    • Universitätsklinikum Schleswig-Holstein, Campus Kiel
  • Mannheim, Germany, 68167
    • Universitätsklinikum Mannheim
  • München, Germany, 80336
    • Klinikum der Universität München, Campus Innenstadt
  • Trier, Germany, 54292
    • Medizinisches Versorgungszentrum der Barmherzigen Brüder Trier
• Poland
  • Poznań, Poland, 48-848
    • Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego Im. Karola Marcinkowskiego w Poznaniu
• United Kingdom
  • Redhill, United Kingdom, RH1 5RH
    • East Surrey Hospital, Surrey and Sussex Healthcare NHS Trust

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 45 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Male or female patients aged 45 to 85 years;
2. Patients having PAOD clinically confirmed (maximal systolic ankle pressures ≤ 70 mmHg or systolic toe pressures ≤ 50 mmHg or transcutaneous partial oxygen pressures (tcp02) ≤ 30 mmHg in supine position) as Rutherford category 5 in at least one lower extremity;
3. Angiography results (DSA, CTA or MRA) for the localization of the high-grade obstruction of an artery of the affected leg (≥ 70 %) that is the leading cause for the ulceration are present and not older than 3 months;
4. One or more clinically relevant and quantifiable ulcer(s) below the ankle with a minimum size of 0.5 cm² per ulcer and a maximum wound size of 20 cm² for all ulcers together;
5. Positive vote of the Advisory Board on the suitability of the wound(s) for enrolment, based on the wound photographs;
6. Patients not eligible for surgical/interventional reconstruction due to technical limitations or comorbidity;
7. No evidence of wound healing after standard of care treatment for at least 1 week before screening;
8. In Patients suffering from 2 or more ulcers at the same extremity, these ulcers must be separated by a minimum bridge of 1 cm of epithelialized skin;
9. If patients are hypertensive, they have to be treated with anti-hypertensive medication according to the applicable guideline;
10. Body mass index (BMI) between 20 and 40 kg/m²;
11. Women of childbearing potential must have a negative blood pregnancy test at screening;
12. Women of childbearing potential and their partner must be willing to use highly effective contraceptive methods during the course of the clinical trial;
13. Patients must be able to consent, have been informed of the nature, the scope and the relevance of the study, voluntarily agree to participation and the study's provisions, and have duly signed the ICF. Subject agrees to comply with the protocol-mandated procedures and visits.

Exclusion Criteria:

1. Patients with skin lesions of leading venous origin or patients suffering from a vasculitis;
2. Patients with thrombangiitis obliterans;
3. Diabetic patients in whom the leading cause for lesions is microangiopathy or neuropathy;
4. Patients with high grade obstruction (≥ 70 %) in the aorto-iliac segment or the common femoral artery as leading cause for skin lesions;
5. Patients with ulcers at the heel due to immobility;
6. Patients with osteomyelitis at ulceration;
7. Patients medicated with vitamin K antagonist, if treatment cannot be stopped before injection or bridged according to applicable guidelines;
8. Patients medicated with DOACs, if they cannot be withheld for 24 hours before injection;
9. Surgical/interventional reconstruction during 1 week before screening (not applicable if it becomes evident during reconstruction that revascularization is not successful: these patients can be included immediately);
10. Patients for whom major amputation is scheduled on target leg;
11. Patients with uncontrolled hypertension defined as systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg; For these patients a re-screening and inclusion into the study will be possible after blood pressure is controlled;
12. Patients who had a myocardial infarction during 3 months before screening;
13. Patients with uncontrolled infection at any of the relevant ulcers;
14. Patients with uncontrolled acute or chronic infection with systemic symptoms;
15. Known serious disease with life expectancy of less than 1 year;
16. Any chronic dermatological disorders diagnosed at the investigator's discretion;
17. Skin disorders, unrelated to the ulcer, that are present adjacent to any of the relevant ulcers;
18. Active malignancy or history of malignancy within 5 years prior to study entry;
19. Patients tested positive for human immunodeficiency virus (HIV˗1, HIV-2), Hepatitis B or Hepatitis C;
20. Any known allergies to components of the IMP;
21. Current or previous (within 30 days of enrolment) treatment with another IMP, or participation and/or under follow-up in another clinical trial;
22. Current use of glucocorticoid-medication above Cushing threshold dose (>7.5 mg/d prednisone or equivalent) or any other prohibited medication or therapy;
23. Known abuse of alcohol, drugs, or medicinal products;
24. Patients anticipated to be unwilling or unable to comply with the requirements of the protocol;
25. Evidence of any other medical conditions (such as psychiatric illness, physical examination, or laboratory findings) that may interfere with the planned treatment, affect the patient's compliance, or place the patient at high risk of complications related to the treatment;
26. Pregnant or lactating woman;
27. Employees of the sponsor, or employees or relatives of the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: allo-APZ2-PAOD; 20-30 intramuscular injections, single dose of allo-APZ2-PAOD, 150 - 225 x 10^6 cells per patient (depending on length of lower leg)	Biological: allo-APZ2-PAOD; Suspension of ABCB5-positive mesenchymal stem cells in pre-filled syringe
Placebo Comparator: Placebo; 20-30 intramuscular injections, vehicle solution (depending on length of lower leg)	Drug: Placebo; Solution for injection in pre-filled syringe

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent change from baseline to week 12 in total wound size of the target leg	Percent change from baseline to week 12 in total wound size of the target leg will be evaluated. The total wound size of the target leg is calculated as sum of the wound sizes of all relevant ulcers of the target leg.	Week 12, or last available post-baseline measurement if the Week 12 measurement is missing.
Assessment of adverse event (AE) occurrence	All AEs occurring during the clinical trial will be registered, documented and evaluated.	Up to 12 months.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to total healing of all relevant ulcers at target leg	Time to total healing of all relevant ulcers at target leg will be evaluated.	A priori specification not possible; between baseline and week 12 post baseline.
Percent change in total wound size of the target leg	Percent change in total wound size of the target leg will be evaluated.	Baseline, week 1, 2, 4, 6, and 8.
Absolute change in total wound size of the target leg	Absolute change in total wound size of the target leg will be evaluated.	Baseline, week 1, 2, 4, 6, 8 and 12.
Ankle-brachial index (ABI) of target leg;	Ankle-brachial index (ABI) of target leg will be evaluated.	Screening Visit, Baseline, Week 2, 4, 8 and 12.
Number of amputated toes at target leg	Number of amputated toes at target leg will be registered, documented and evaluated.	A priori specification not possible; between baseline and week 12 post baseline.
Time to major amputation at target leg until week 12;	Time to major amputation at target leg until week 12 will be evaluated.	A priori specification not possible; between baseline and week 12 post baseline.
Assessment of epithelialization in % of wound area of all relevant ulcers of the target leg	Epithelialization of all relevant ulcers of the target leg will be evaluated by the investigator based on image analysis for each ulcer individually.	Day 0 prior IMP-application, week 2, 4, 8 and 12.
Assessment of further wound healing parameters: formation of granulation tissue in % of wound area and wound exudation of all relevant ulcers of the target leg	Formation of granulation tissue in % of wound area will be assessed by the investigator based on image analysis for each ulcer individually. Wound exudation of all relevant ulcers of the target leg will be evaluated as high-moderate-low based on amounts of fluid on the wound.	Day 0 prior IMP-application, week 2, 4, 8 and 12.
Assessment of quality of life (QoL) using the short form 36 (SF-36) questionnaire	Quality of life (QoL) using the short form 36 (SF-36) questionnaire will be evaluated. The SF-36 questionnaire is a self-administered questionnaire containing 36 items. It measures health on eight multi-item dimensions, covering functional status, well being, and overall evaluation of health.	Day 0 prior IMP-application, week 2, 8 and 12.
Pain assessment as per numerical rating scale (NRS).	Pain assessment as per numerical rating scale (NRS) will be evaluated.	Day 0 prior IMP-application, week 2, 4, 8 and 12.
Physical examination at week 12;	A full physical examination will be performed at week 12 and abnormal physical examination results will be evaluated and reported as AEs.	Week 12.
Vital signs: Body temperature at week 12;	Body temperature at week 12 will be evaluated.	Week 12.
Vital signs: Blood pressure at week 12;	Blood pressure at week 12 will be evaluated.	Week 12.
Vital signs: Heart rate at week 12;	Heart rate at week 12 will be evaluated.	Week 12.
Assessment of Laboratory values (Hematology) at Week 12:	The Hematology values will be measured and evaluated at Week 12	Week 12.
Assessment of Laboratory values (Clinical chemistry) at Week 12	The clinical chemistry values will be measured and evaluated at Week 12.	Week 12.
Time to major amputation	Time to major amputation will be evaluated.	A priori specification not possible; between baseline and month 12 post baseline.

Collaborators and Investigators

• Sponsor: RHEACELL GmbH & Co. KG
• Collaborators: FGK Clinical Research GmbH; Ticeba GmbH; Granzer Regulatory Consulting & Services
• Investigators: Principal Investigator: Oliver Müller, Prof. Dr., Christian-Albrechts-Universität zu Kiel, Klinik für Innere Medizin III Kardiologie, Angiologie und internistische Intensivmedizin, Kiel, Germany

Study record dates

Study Major Dates

• Study Start (Actual): March 5, 2018
• Primary Completion (Actual): May 15, 2020
• Study Completion (Actual): May 15, 2020

Study Registration Dates

• First Submitted: October 11, 2017
• First Submitted That Met QC Criteria: November 9, 2017
• First Posted (Actual): November 13, 2017

Study Record Updates

• Last Update Posted (Actual): June 29, 2020
• Last Update Submitted That Met QC Criteria: June 25, 2020
• Last Verified: June 1, 2020

More Information

Terms related to this study

• Keywords: mesenchymal stem cells; allogeneic; Peripheral Arterial Occlusive Disease; ABCB5; advanced therapy medicinal product; somatic cell therapy; phase I/IIa; non-healing ulcers
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Arteriosclerosis; Atherosclerosis; Peripheral Vascular Diseases; Peripheral Arterial Disease; Arterial Occlusive Diseases
• Other Study ID Numbers: allo-APZ2-PAOD-II-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No